Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol

Journal of Allergy and Clinical Immunology

Volumn 108, Issue 6, 2001, Pages 938-945

  Milgrom, Henry ^a,b   Skoner, David P ^a,c   Bensch, George ^a,d   Kim, Kenneth T ^a,e   Claus, Raymond ^a,e   Baumgartner, Rudolf A ^a,f  

^a National Jewish Medical and Research Center ^*  (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d Bensch Research Associates   (United States)

^e Allergy Asthma Et Resp Care Center   (United States)

^f Sepracor Inc   (United Kingdom)

Author keywords

(R) albuterol; (S) albuterol; Asthma; Bronchodilator; FEV1; Levalbuterol; Pediatric; Racemic albuterol; agonist

Indexed keywords

LEVALBUTEROL; PLACEBO; SALBUTAMOL;

ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0035217690     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.120134     Document Type: Article

References (25)

1. Asthma from the perspective of the patient
2. Pediatric asthma: Promoting best practice
3. Comparison of R-, S-, and RS-albuterol interaction with human β1- and β2-adrenergic receptors
4. Regular inhaled beta-agonist treatment in bronchial asthma
5. The use of β-agonists and the risk of death and near death from asthma
6. FDA 1992 policy statement for the development of new stereoisomeric drugs
7. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle
8. Effects of enantiomers of β2 agonists on ACh release and smooth muscle contraction in the trachea
9. Ketotifen inhibits exacerbation of allergic airway hyperreactivity by racemic salbutamol in the guinea pig
10. Exacerbation of airway hyperreactivity by (±) salbutamol in sensitized guinea pigs
11. Anomalous effects of albuterol and other sympathomimetics in the guinea pig
12. Effects of S-salbutamol on isolated human bronchus
13. Salbutamol in the treatment of asthma
14. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers
15. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects
16. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol
17. Improved bronchodilation with levalbuterol compared to racemic albuterol in patients with asthma
18. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients
19. Standardization of spirometry: 1994 update
20. Absolute configuration of the optical isomers of salbutamol
21. Package labeling for Ventolin Inhalation Solution
22. Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation